Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dhruvkumar Soni

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Advanced Drug Delivery Reviews|January 11, 2021
Nanocarrier vaccines for SARS-CoV-2Jatin Machhi, Farah Shahjin, Srijanee Das, et al.
Nature Biomedical Engineering|July 18, 2025
Sensitization of tumours to immunotherapy by boosting early type-I interferon responses enables epitope spreadingSadeem Qdaisat, Brandon Wummer, Brian D Stover, et al.
Nature|October 22, 2025
SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockadeAdam J Grippin, Christiano Marconi, Sage Copling, et al.
Cell|May 2, 2024
RNA aggregates harness the danger response for potent cancer immunotherapyHector R Mendez-Gomez, Anna DeVries, Paul Castillo, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Advanced Drug Delivery Reviews|January 11, 2021
Nanocarrier vaccines for SARS-CoV-2Jatin Machhi, Farah Shahjin, Srijanee Das, et al.
Nature Biomedical Engineering|July 18, 2025
Sensitization of tumours to immunotherapy by boosting early type-I interferon responses enables epitope spreadingSadeem Qdaisat, Brandon Wummer, Brian D Stover, et al.
Nature|October 22, 2025
SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockadeAdam J Grippin, Christiano Marconi, Sage Copling, et al.
Cell|May 2, 2024
RNA aggregates harness the danger response for potent cancer immunotherapyHector R Mendez-Gomez, Anna DeVries, Paul Castillo, et al.
Pageof 2